Topic

Articles

How engaging with digital influencers holds the key for medical affairs.

Bridging the Generational Chasm in Oncology

Gabriela Marton is Regulatory Affairs Director and Quality Director at Arriello, where she leads the regulatory affairs functions, developing robust and efficient market access and post-marketing strategies to support pharmaceutical companies’ business needs. She has over 14 years’ experience in regulatory affairs and compliance within the pharmaceutical and food supplements sectors. Previously, she was an independent regulatory consultant, and has held several positions in regulatory affairs and compliance in various pharmaceutical companies, one of which is GSK where she started her regulatory career and worked for almost a decade.

If the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.

Bringing Biosimilars to Market in Europe

Janardan Prasad is CBO and Head of Life Sciences at Lore IO, providers of a pre-built, AI-powered common data model that enables unified data views and faster vendor onboarding. To learn more, visit the company at 

Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.

How Just-in-Time Data Can Clear the Path to First Drug Launch

A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.

Critical Connection: Patient Services and Product Launch

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com

Tips for rounding out the rough edges in crossover.

Mastering the Transition From Academia to Industry

Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.

Injecting Traditional Scientific Exchange with New Life

Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability. 

Commercial Sustainability of Pharmaceutical Innovations for Pandemics

Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.

Best Practices for Balancing Medical Affairs Globalization with Local Requirements

In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.

Manage Risk Effectively to Improve the Value of Your Alliance

Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.

Strategy